Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V.
PMID: 34859382
Neurotherapeutics. 2021 Dec 03; doi: 10.1007/s13311-021-01165-9. Epub 2021 Dec 03.

The potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the...

Cite
Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021;doi: 10.1007/s13311-021-01165-9.
Capone, F., Lucchini, M., Ferraro, E., Bianco, A., Rossi, M., Cicia, A., Cortese, A., Cruciani, A., De Arcangelis, V., De Giglio, L., Motolese, F., Sancetta, B., Mirabella, M., & Di Lazzaro, V. (2021). Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, . https://doi.org/10.1007/s13311-021-01165-9
Capone, Fioravante, et al. "Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. (2021). doi: https://doi.org/10.1007/s13311-021-01165-9
Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021 Dec 03; doi: 10.1007/s13311-021-01165-9. Epub 2021 Dec 03. PMID: 34859382; PMCID: PMC8639214.
Copy Download .nbib Format: NLM
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

Oncotarget

Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R.
PMID: 29581839
Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 06.

Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients failing imatinib. Direct comparisons between dasatinib and nilotinib...

Cite
Tiribelli M, Bonifacio M, Binotto G, et al. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget. 2018;9(18):14219-14227doi: 10.18632/oncotarget.24478.
Tiribelli, M., Bonifacio, M., Binotto, G., Iurlo, A., Cibien, F., Maino, E., Guella, A., Festini, G., Minotto, C., De Biasi, E., De Marchi, F., Scaffidi, L., Frison, L., Bucelli, C., Medeot, M., Calistri, E., Sancetta, R., Stulle, M., Orofino, N., Krampera, M., Gherlinzoni, F., Semenzato, G., Pizzolo, G., Ambrosetti, A., & Fanin, R. (2018). Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget, 9(18), 14219-14227. https://doi.org/10.18632/oncotarget.24478
Tiribelli, Mario, et al. "Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients." Oncotarget vol. 9,18 (2018): 14219-14227. doi: https://doi.org/10.18632/oncotarget.24478
Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 06. PMID: 29581839; PMCID: PMC5865665.
Copy Download .nbib Format: NLM
Diatoms as hydrographic tracers: example from bering sea sediments.

Science (New York, N.Y.)

Sancetta C.
PMID: 17748025
Science. 1981 Jan 16;211(4479):279-81. doi: 10.1126/science.211.4479.279.

Variations in the distribution of diatom species in surface sediments mirror distinct hydrographic regimes on the Bering shelf. Spring salinity fronts divide the water column into four zones with different vertical structures and different productivity patterns. Four assemblages of...

Cite
Sancetta C. Diatoms as hydrographic tracers: example from bering sea sediments. Science. 1981;211(4479):279-81doi: 10.1126/science.211.4479.279.
Sancetta, C. (1981). Diatoms as hydrographic tracers: example from bering sea sediments. Science (New York, N.Y.), 211(4479), 279-81. https://doi.org/10.1126/science.211.4479.279
Sancetta, C. "Diatoms as hydrographic tracers: example from bering sea sediments." Science (New York, N.Y.) vol. 211,4479 (1981): 279-81. doi: https://doi.org/10.1126/science.211.4479.279
Sancetta C. Diatoms as hydrographic tracers: example from bering sea sediments. Science. 1981 Jan 16;211(4479):279-81. doi: 10.1126/science.211.4479.279. PMID: 17748025.
Copy Download .nbib Format: NLM
Burkitt lymphoma in adolescents and young adults: management challenges.

Adolescent health, medicine and therapeutics

Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R.
PMID: 28096698
Adolesc Health Med Ther. 2016 Dec 23;8:11-29. doi: 10.2147/AHMT.S94170. eCollection 2017.

About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25-40 years, based on selection criteria used in...

Cite
Dozzo M, Carobolante F, Donisi PM, et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2016;8:11-29doi: 10.2147/AHMT.S94170.
Dozzo, M., Carobolante, F., Donisi, P. M., Scattolin, A., Maino, E., Sancetta, R., Viero, P., & Bassan, R. (2017). Burkitt lymphoma in adolescents and young adults: management challenges. Adolescent health, medicine and therapeutics, 811-29. https://doi.org/10.2147/AHMT.S94170
Dozzo, Massimo, et al. "Burkitt lymphoma in adolescents and young adults: management challenges." Adolescent health, medicine and therapeutics vol. 8 (2017): 11-29. doi: https://doi.org/10.2147/AHMT.S94170
Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2016 Dec 23;8:11-29. doi: 10.2147/AHMT.S94170. eCollection 2017. PMID: 28096698; PMCID: PMC5207020.
Copy Download .nbib Format: NLM
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study.

HemaSphere

Visentin A, Nasillo V, Marchetti M, Ferrarini I, Paolini R, Sancetta R, Rigolin GM, Cibien F, Riva M, Briani C, Marinello S, Piazza F, Gherlinzoni F, Krampera M, Bassan R, Cuneo A, Luppi M, Semenzato G, Marasca R, Trentin L.
PMID: 32647801
Hemasphere. 2020 Jun 08;4(3):e395. doi: 10.1097/HS9.0000000000000395. eCollection 2020 Jun.

No abstract available.

Cite
Visentin A, Nasillo V, Marchetti M, et al. Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. Hemasphere. 2020;4(3):e395doi: 10.1097/HS9.0000000000000395.
Visentin, A., Nasillo, V., Marchetti, M., Ferrarini, I., Paolini, R., Sancetta, R., Rigolin, G. M., Cibien, F., Riva, M., Briani, C., Marinello, S., Piazza, F., Gherlinzoni, F., Krampera, M., Bassan, R., Cuneo, A., Luppi, M., Semenzato, G., Marasca, R., & Trentin, L. (2020). Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 4(3), e395. https://doi.org/10.1097/HS9.0000000000000395
Visentin, Andrea, et al. "Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study." HemaSphere vol. 4,3 (2020): e395. doi: https://doi.org/10.1097/HS9.0000000000000395
Visentin A, Nasillo V, Marchetti M, Ferrarini I, Paolini R, Sancetta R, Rigolin GM, Cibien F, Riva M, Briani C, Marinello S, Piazza F, Gherlinzoni F, Krampera M, Bassan R, Cuneo A, Luppi M, Semenzato G, Marasca R, Trentin L. Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. Hemasphere. 2020 Jun 08;4(3):e395. doi: 10.1097/HS9.0000000000000395. eCollection 2020 Jun. PMID: 32647801; PMCID: PMC7306307.
Copy Download .nbib Format: NLM
Some aspects of the hepatic changes associated with heart failure.

The American journal of gastroenterology

SANCETTA SM.
PMID: 14496723
Am J Gastroenterol. 1962 Jul;38:51-5.

No abstract available.

Cite
SANCETTA SM. Some aspects of the hepatic changes associated with heart failure. Am J Gastroenterol. 1962;38:51-5
SANCETTA, S. M. (1962). Some aspects of the hepatic changes associated with heart failure. The American journal of gastroenterology, 3851-5.
SANCETTA, S M. "Some aspects of the hepatic changes associated with heart failure." The American journal of gastroenterology vol. 38 (1962): 51-5.
SANCETTA SM. Some aspects of the hepatic changes associated with heart failure. Am J Gastroenterol. 1962 Jul;38:51-5. PMID: 14496723.
Copy Download .nbib Format: NLM
Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.

Mediterranean journal of hematology and infectious diseases

Maino E, Scattolin AM, Viero P, Sancetta R, Pascarella A, Vespignani M, Bassan R.
PMID: 25574360
Mediterr J Hematol Infect Dis. 2015 Jan 01;7(1):e2015001. doi: 10.4084/MJHID.2015.001. eCollection 2015.

The introduction of newer cytotoxic monoclonal antibodies and chimeric antigen receptor modified T cells is opening a new age in the management of B-lineage adult acute lymphoblastic leukemia. This therapeutic change must be very positively acknowledged because of the...

Cite
Maino E, Scattolin AM, Viero P, et al. Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterr J Hematol Infect Dis. 2015;7(1):e2015001doi: 10.4084/MJHID.2015.001.
Maino, E., Scattolin, A. M., Viero, P., Sancetta, R., Pascarella, A., Vespignani, M., & Bassan, R. (2015). Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterranean journal of hematology and infectious diseases, 7(1), e2015001. https://doi.org/10.4084/MJHID.2015.001
Maino, Elena, et al. "Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells." Mediterranean journal of hematology and infectious diseases vol. 7,1 (2015): e2015001. doi: https://doi.org/10.4084/MJHID.2015.001
Maino E, Scattolin AM, Viero P, Sancetta R, Pascarella A, Vespignani M, Bassan R. Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterr J Hematol Infect Dis. 2015 Jan 01;7(1):e2015001. doi: 10.4084/MJHID.2015.001. eCollection 2015. PMID: 25574360; PMCID: PMC4283921.
Copy Download .nbib Format: NLM
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.

British journal of haematology

Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, Binotto G, Bocchia M, Bonifacio M, Caocci G, Capodanno I, Castagnetti F, Cavazzini F, Crisà E, Crugnola M, Stella De Candia M, Elena C, Fava C, Galimberti S, Gozzini A, Gugliotta G, Intermesoli T, Iurlo A, La Barba G, Latagliata R, Leonetti Crescenzi S, Levato L, Loglisci G, Lucchesi A, Luciano L, Lunghi F, Luzi D, Malato A, Cristina Miggiano M, Pizzuti M, Pregno P, Rapezzi D, Rege-Cambrin G, Rosti G, Russo S, Sancetta R, Rita Scortechini A, Sorà F, Sportoletti P, Stagno F, Tafuri A, Tiribelli M, Foà R, Saglio G.
PMID: 34636033
Br J Haematol. 2021 Oct 11; doi: 10.1111/bjh.17890. Epub 2021 Oct 11.

Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the...

Cite
Breccia M, Abruzzese E, Accurso V, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2021;doi: 10.1111/bjh.17890.
Breccia, M., Abruzzese, E., Accurso, V., Attolico, I., Barulli, S., Bergamaschi, M., Binotto, G., Bocchia, M., Bonifacio, M., Caocci, G., Capodanno, I., Castagnetti, F., Cavazzini, F., Crisà, E., Crugnola, M., Stella De Candia, M., Elena, C., Fava, C., Galimberti, S., Gozzini, A., Gugliotta, G., Intermesoli, T., Iurlo, A., La Barba, G., Latagliata, R., Leonetti Crescenzi, S., Levato, L., Loglisci, G., Lucchesi, A., Luciano, L., Lunghi, F., Luzi, D., Malato, A., Cristina Miggiano, M., Pizzuti, M., Pregno, P., Rapezzi, D., Rege-Cambrin, G., Rosti, G., Russo, S., Sancetta, R., Rita Scortechini, A., Sorà, F., Sportoletti, P., Stagno, F., Tafuri, A., Tiribelli, M., Foà, R., & Saglio, G. (2021). COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British journal of haematology, . https://doi.org/10.1111/bjh.17890
Breccia, Massimo, et al. "COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17890
Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, Binotto G, Bocchia M, Bonifacio M, Caocci G, Capodanno I, Castagnetti F, Cavazzini F, Crisà E, Crugnola M, Stella De Candia M, Elena C, Fava C, Galimberti S, Gozzini A, Gugliotta G, Intermesoli T, Iurlo A, La Barba G, Latagliata R, Leonetti Crescenzi S, Levato L, Loglisci G, Lucchesi A, Luciano L, Lunghi F, Luzi D, Malato A, Cristina Miggiano M, Pizzuti M, Pregno P, Rapezzi D, Rege-Cambrin G, Rosti G, Russo S, Sancetta R, Rita Scortechini A, Sorà F, Sportoletti P, Stagno F, Tafuri A, Tiribelli M, Foà R, Saglio G. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2021 Oct 11; doi: 10.1111/bjh.17890. Epub 2021 Oct 11. PMID: 34636033; PMCID: PMC8652631.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries